- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
How We Treat HER2-Positive Metastatic Breast Cancer ; volume:42 ; number:04 ; year:2021 ; pages:370-375
Indian journal of medical & paediatric oncology ; 42, Heft 04 (2021), 370-375
- Contributor
-
Komaranchath, Ashok S.
Mathew, Aju
- DOI
-
10.1055/s-0041-1731861
- URN
-
urn:nbn:de:101:1-2022031911044274333704
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:34 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Komaranchath, Ashok S.
- Mathew, Aju
Other Objects (12)
ASCO 2019: highlights in HER2-positive metastatic breast cancer
ASCO 2018: highlights in HER2-positive metastatic breast cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
New Systemic Therapy Strategies for HER2-Positive Metastatic Breast Carcinoma
Current Standards and Future Outlooks in Metastatic Her2-Positive Breast Cancer
New Therapeutic Strategies in Advanced Nonoperable or Metastatic HER2-positive Breast Cancer
Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update
SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer
Cost of illness of HER2-positive and metastatic and recurrent HER2-positive breast cancer – a Danish register-based study from 2005 to 2016
Phase I study of LZM005 in patients with HER2-positive metastatic breast cancer
Treatment Options for Patients with Brain Metastatic Disease in HER2-Positive Breast Cancer
Trastuzumab therapy duration in HER2-positive de novo metastatic breast cancer: 1999–2018
ASCO 2019: highlights in HER2-positive metastatic breast cancer
ASCO 2018: highlights in HER2-positive metastatic breast cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
New Systemic Therapy Strategies for HER2-Positive Metastatic Breast Carcinoma
Current Standards and Future Outlooks in Metastatic Her2-Positive Breast Cancer
New Therapeutic Strategies in Advanced Nonoperable or Metastatic HER2-positive Breast Cancer
Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update
SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer
Cost of illness of HER2-positive and metastatic and recurrent HER2-positive breast cancer – a Danish register-based study from 2005 to 2016
Phase I study of LZM005 in patients with HER2-positive metastatic breast cancer
Treatment Options for Patients with Brain Metastatic Disease in HER2-Positive Breast Cancer
Trastuzumab therapy duration in HER2-positive de novo metastatic breast cancer: 1999–2018
ASCO 2019: highlights in HER2-positive metastatic breast cancer
ASCO 2018: highlights in HER2-positive metastatic breast cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
New Systemic Therapy Strategies for HER2-Positive Metastatic Breast Carcinoma
Current Standards and Future Outlooks in Metastatic Her2-Positive Breast Cancer
New Therapeutic Strategies in Advanced Nonoperable or Metastatic HER2-positive Breast Cancer
Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update
SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer
Cost of illness of HER2-positive and metastatic and recurrent HER2-positive breast cancer – a Danish register-based study from 2005 to 2016
Phase I study of LZM005 in patients with HER2-positive metastatic breast cancer
Treatment Options for Patients with Brain Metastatic Disease in HER2-Positive Breast Cancer